B.C. Government Faces Pressure Over Rare Disease Drug Program

The British Columbia government has yet to implement reforms to its expensive drugs program for rare diseases, despite Premier David Eby recognizing the system’s inadequacies five months ago. This inaction follows significant public criticism stemming from the handling of the case involving Charleigh Pollock, a ten-year-old from Vancouver Island suffering from Batten disease, a rare neurodegenerative condition for which no cure currently exists.

In early 2023, the B.C. government initially supported an expert committee’s recommendation to discontinue a treatment costing over $800,000 annually. However, after facing intense public outcry, the government reversed its decision, citing input from experts in the United States.

Responding to inquiries from Postmedia News this month, the B.C. Health Ministry confirmed that a review of the drug funding process is still in progress. “We will have information to share once it’s complete,” said Calvin Cen, a senior public affairs officer for the ministry. The duration of the review remains unspecified, and Health Minister Josie Osborne has not been available for interviews.

The internal review aims to enhance the expensive-drugs-for-rare-diseases program to better serve patients, families, and decision-makers, according to the ministry. It seeks to create a more transparent and responsive system where patients and families feel supported and informed about the processes affecting their treatment.

Officials acknowledge the need to improve public understanding of how this process operates. “Greater transparency can help build trust and ensure that patients and families feel heard and informed as decisions are made,” the ministry stated in its response.

The fallout from the government’s initial decision was significant. Following the reinstatement of treatment for Pollock, ten members of the 58-member provincial advisory committee resigned, and none have returned. Although the remaining members can still constitute a quorum, the drug approval process has continued as before, according to ministry officials.

Premier Eby has emphasized the need for changes to improve transparency in the rare disease treatment system. In July, he criticized the existing structure, which involved a committee making decisions behind closed doors without public engagement. He stated, “We have to figure out a way that works for the doctors and experts advising on whether or not a particular patient should receive a particular treatment.”

Osborne also voiced the importance of transparency, reiterating that it is essential for fostering trust and ensuring that patients feel their voices are heard.

Notably, a Postmedia investigation revealed that many U.S. experts the B.C. government consulted when reinstating the costly treatment had connections to the pharmaceutical company producing the drug or to foundations advocating for its use. This raised concerns regarding potential conflicts of interest.

Moreover, a previous B.C. government review from four years prior had already recommended enhancements to transparency and decision-making processes related to rare disease treatments. It warned of the urgency to address the anticipated increase in spending on rare disease drugs, projected to reach $600 million annually by the end of the decade. Yet, implementation of these recommendations has been minimal, according to informed sources.

While the Health Ministry claims that the majority of the recommendations from this earlier report have been acted upon or are part of ongoing efforts, officials pointed to only two completed items out of over 300 suggested changes: the creation of a web page to support transparency and the establishment of an appeal process. The recommendations for increased oversight, public engagement, and a comprehensive communication strategy remain largely unaddressed.

As the situation unfolds, the pressure mounts on the B.C. government to deliver a more effective and transparent system for funding and treating rare diseases. The ongoing review must not only address the immediate concerns raised by families like that of Charleigh Pollock but also ensure that the decisions made in the future are grounded in public trust and expert guidance.